Endocrine Abstracts

CA19-9 (sialyl Lewis[a] antigen) was originally described as a gastrointestinal system and pancreas specific tumour marker. Immunohistochemical studies have demonstrated that CA19-9 is expressed in both differentiated and anaplastic thyroid carcinomas. Increased serum levels of CA 19-9 were reported in few patients with anaplastic thyroid cancer; however, to the best of our knowledge, there is no previous report about serum levels of CA 19-9 in differentiated thyroid cancer. S...